Virios Therapeutics shares are trading lower after the company announced a proposed public offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study.
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics shares are trading lower following the announcement of a proposed public offering to fund preparatory activities for its planned IMC-2 Long-COVID Phase 2b study.
May 17, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Virios Therapeutics shares are trading lower after the company announced a proposed public offering to fund preparatory activities for its planned IMC-2 Long-COVID Phase 2b study.
The announcement of a public offering typically leads to a dilution of existing shares, which can negatively impact the stock price in the short term. The funds are intended for the IMC-2 Long-COVID Phase 2b study, which is a positive development, but the immediate market reaction is likely to be negative due to the dilution effect.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100